CN106265631A - Biochanin A purposes in preparation suppression breast carcinoma propagation, diversion medicaments and mammary cancer chemotherapy sensitizer - Google Patents
Biochanin A purposes in preparation suppression breast carcinoma propagation, diversion medicaments and mammary cancer chemotherapy sensitizer Download PDFInfo
- Publication number
- CN106265631A CN106265631A CN201610902969.7A CN201610902969A CN106265631A CN 106265631 A CN106265631 A CN 106265631A CN 201610902969 A CN201610902969 A CN 201610902969A CN 106265631 A CN106265631 A CN 106265631A
- Authority
- CN
- China
- Prior art keywords
- biochanin
- breast carcinoma
- purposes
- propagation
- zeb1
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides Biochanin A (Biochanin A) and at preparation suppression breast carcinoma propagation, the medicine of transfer and prepare the purposes in mammary cancer chemotherapy sensitizer.The compound that the present invention relates to has and reduces the effect of ZEB1 gene expression in breast carcinoma, and and then the suppression propagation of breast carcinoma, transfer and chemotherapy resistance, show stronger breast cancer inhibition effect and Chemosensitizing effect, thus for the new strategy of breast cancer treatment offer.
Description
Technical field
The invention provides the new application of Biochanin A (Biochanin A), relate to Biochanin A
(Biochanin A) is at the table of preparation suppression ZEB1 (zinc refer to-containing homology frame transcription regulaton factor delta-globulin enhancer 1)
Reach, and then suppress the propagation of breast carcinoma, the medicine of transfer and prepare the application in mammary cancer chemotherapy sensitizer, belong to biological doctor
Medicine field.
Background technology
Breast carcinoma occupies the first place of female malignant sickness rate the most in the world, and it is dead to become female malignant
The one of the main reasons died.Although the treatment of breast carcinoma has been obtained for significant progress, but still has many patients to die from
The chemotherapy resistance of breast carcinoma, recur and recur the transfer brought.
Numerous researchs show, ZEB1 plays an important role in propagation, transfer and the chemotherapy resistance of breast carcinoma, but
Now still without the inhibitor of ZEB1.Therefore, the inhibitor of exploitation ZEB1, as a new target spot, mammary gland can be given
The treatment of cancer provides new strategy.
A kind of natural extract compound of Biochanin A (Biochanin A), is mainly derived from leguminous plant chickpea kind
The germ fraction of son, Herba Trifolii Pratentis herb etc..
Summary of the invention
The problem that the purpose of the present invention solves how to suppress ZEB1 to express, it is provided that a kind of Biochanin A (Biochanin
A) new application, i.e. Biochanin A are in the expression of preparation suppression ZEB1, and then the suppression propagation of breast carcinoma, the medicine of transfer
And prepare the application in chemotherapy resistance sensitizer.
The invention provides Biochanin A (Biochanin A) to express and the medicine of relevant disease at preparation suppression ZEB1
Purposes in thing.
Medicine of the present invention includes: ZEB1 micromolecular inhibitor；Suppression breast carcinoma propagation and the medicine of transfer；And
Mammary cancer chemotherapy sensitizer.
Biochanin A of the present invention (Biochanin A) is in the expression of preparation suppression ZEB1, and then suppression mammary gland
The propagation of cancer, the medicine of transfer and prepare the application in mammary cancer chemotherapy sensitizer, specifically include herein below:
1. the vivoexpression of Biochanin A (Biochanin A) suppression ZEB1 is proved by Western Blot experiment
Biochanin A (Biochanin A) can suppress the expression of ZEB1 in breast cancer cell.
2. Biochanin A (Biochanin A) suppression breast carcinoma propagation and the in vitro study of transfer
(1) tested by CCK-8 and confirm that Biochanin A (Biochanin A) is to breast cancer cell MDA-MB-in vitro
231 have grown inhibitory action；
(2) tested by Transwell and confirm that Biochanin A (Biochanin A) is to breast cancer cell in vitro
The migration of MDA-MB-231 plays inhibitory action.
3. Biochanin A (Biochanin A) promotes that the in vitro study of mammary cancer chemotherapy enhanced sensitivity is existed by CCK-8 experiment
External confirmation Biochanin A (Biochanin A) can strengthen chemotherapeutics epirubicin (Epirubicin) to breast carcinoma
The inhibitory action of cell MDA-MB-231 growth.
4. the propagation of the expression of Biochanin A (Biochanin A) suppression ZEB1, and then suppression breast carcinoma, and promote
Enter the In vivo study of mammary cancer chemotherapy sensitizer
(1) Female nude mice of 4-6 week old, often group 5 are selected.With 2.0 × 106/ quantity only, inoculates human breast cancer cell
MDA-MB-231；
(2) when tumor growth to certain volume, it is respectively adopted the mode of intraperitoneal administration every other day and gavage every other day, gives table
Soft than star (5mg/kg) and Biochanin A (100mg/kg)；
(3), after being administered two weeks, put to death nude mice, tumor is taken pictures；
(4) the tumor body tag that will take off, 4% paraformaldehyde fixes, and dehydration, paraffin embedding, cuts into slices and carries out pathological staining,
The expression of ZEB1 in detection different disposal group.
Advantages of the present invention and good effect:
The Biochanin A (Biochanin A) that the present invention provides can suppress the expression of ZEB1, for ZEB1 inhibitor
Preparation provides strategy；Biochanin A (Biochanin A) can suppress propagation and the transfer of breast carcinoma, for breast carcinoma
Treatment provides new drug；By by Biochanin A (Biochanin A) and epirubicin use in conjunction, breast carcinoma can be solved
Chemotherapy resistance problem.
Accompanying drawing explanation
The molecular structural formula of Fig. 1 Biochanin A (Biochanin A)；
Fig. 2 Biochanin A (Biochanin A) suppresses the expression of ZEB1 in breast cancer cell MDA-MB-231；
Fig. 3 Biochanin A (Biochanin A) suppresses it to breed in breast cancer cell MDA-MB-231；
Fig. 4 Biochanin A (Biochanin A) suppresses it to migrate in breast cancer cell MDA-MB-231；
Fig. 5 Biochanin A (Biochanin A) improves the growth of epirubicin in breast cancer cell MDA-MB-231
Rejection ability；
Fig. 6 Biochanin A (Biochanin A) suppression breast carcinoma propagation and the In vivo study of raising chemotherapy sensitizing；
Fig. 7 Biochanin A (Biochanin A) research to ZEB1 expression inhibiting in vivo.
The present invention combines the drawings and specific embodiments and is described in further details.
Detailed description of the invention
Embodiment 1
The expression of Biochanin A (Biochanin A) suppression ZEB1
After Biochanin A (Biochanin A) processes MDA-MB-231 cell 48h, extract albumen, pass through
The expression of WesternBlot detection ZEB1；The immunohistochemical experiment of experiment in vivo has also probed into Biochanin A simultaneously
(Biochanin A) impact on ZEB1 expression.
As shown in Figure 2 and Figure 7, Fig. 2 Western Blot result shows Biochanin A (Biochanin A) place to result
After reason MDA-MB-231 cell, the expression of ZEB1 is substantially suppressed, Fig. 7 Showed by immune group result Biochanin A
(Biochanin A) processes after mice, and in its tumor, the expression of ZEB1 is substantially suppressed, and this is that the preparation of ZEB1 inhibitor carries
Supply new application.
Embodiment 2
The propagation of Biochanin A (Biochanin A) suppression breast cancer cell
(1) 96 orifice plate, every hole 3000 MDA-MB-231 cells of paving, culture plate is put into incubator.
(2) Biochanin A (Biochanin A) or DMSO process MDA-MB-231 cell 24h, 48h, 72h respectively.
(3) CCK-8 method detection Biochanin A (Biochanin A) inhibitory action to breast cancer cell.
As it is shown on figure 3, Biochanin A (Biochanin A) can substantially suppress the multiplication capacity of breast cancer cell.
Embodiment 3
The transfer of Biochanin A (Biochanin A) suppression breast cancer cell
(1) take MDA-MB-231 cell suspension 200uL and add Transwell cell, use Biochanin A respectively
(Biochanin A) or DMSO process.
Under (2) 24 orifice plates, room adds the full culture medium of 500uL, cellar culture 48h.
(3) wipe the cell of upper indoor with cotton swab, violet staining, after three hours, is taken pictures and adds up.
As shown in Figure 4, Biochanin A (Biochanin A) can substantially suppress the transfer ability of breast cancer cell.
Embodiment 4
Biochanin A (Biochanin A) improves the epirubicin rejection ability to breast carcinoma
(1) 96 orifice plate, every hole 3000 MDA-MB-231 cells of paving, culture plate is put into incubator.
(2) DMSO, Biochanin A (Biochanin A), epirubicin or Biochanin A (Biochanin A) and
Epirubicin processes MDA-MB-231 cell 48h respectively.
(3) CCK-8 method detection Biochanin A (Biochanin A) and epirubicin are used in combination breast carcinoma thin
The inhibitory action of born of the same parents.
As it is shown in figure 5, Biochanin A (Biochanin A) can significantly improve the epirubicin suppression to breast carcinoma
Ability.
Embodiment 5
Biochanin A (Biochanin A) suppression breast carcinoma propagation and the In vivo study of raising chemotherapy sensitizing
(1) Female nude mice of 4-6 week old, often group 5 are selected.With 2.0 × 106/ quantity only, inoculates human breast cancer cell
MDA-MB-231；
(2) when tumor growth to certain volume, it is respectively adopted the mode of intraperitoneal administration every other day and gavage every other day, gives table
Soft than star (5mg/kg) and Biochanin A (100mg/kg)；
(3), after being administered two weeks, put to death nude mice, tumor is taken pictures.
As shown in Figure 6, Biochanin A (Biochanin A) can substantially suppress the growth of tumor, and can improve
The tumor killing effect of epirubicin.
Claims (4)
1. the Biochanin A (BiochaninA) purposes in the medicine of preparation suppression ZEB1 expression and relevant disease.
Purposes the most according to claim 1, it is characterised in that described medicine is ZEB1 micromolecular inhibitor.
Purposes the most according to claim 1, it is characterised in that described medicine is suppression breast carcinoma propagation, the medicine of transfer
Thing.
Purposes the most according to claim 1, it is characterised in that described medicine is mammary cancer chemotherapy sensitizer.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610902969.7A CN106265631A (en) | 2016-10-17 | 2016-10-17 | Biochanin A purposes in preparation suppression breast carcinoma propagation, diversion medicaments and mammary cancer chemotherapy sensitizer |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610902969.7A CN106265631A (en) | 2016-10-17 | 2016-10-17 | Biochanin A purposes in preparation suppression breast carcinoma propagation, diversion medicaments and mammary cancer chemotherapy sensitizer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106265631A true CN106265631A (en) | 2017-01-04 |
Family
ID=57717948
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610902969.7A Pending CN106265631A (en) | 2016-10-17 | 2016-10-17 | Biochanin A purposes in preparation suppression breast carcinoma propagation, diversion medicaments and mammary cancer chemotherapy sensitizer |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106265631A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110317872A (en) * | 2019-07-15 | 2019-10-11 | 汕头大学医学院第一附属医院 | It is used to prepare the molecular marked compound and kit of detection, prognosis and Diagnosis of Breast cancer product |
| CN113842387A (en) * | 2021-11-19 | 2021-12-28 | 大连理工大学盘锦产业技术研究院 | Pharmaceutical composition of 10-hydroxycamptothecin and biochanin A and application thereof |
| CN115335045A (en) * | 2020-03-30 | 2022-11-11 | 雷根斯堡大学 | Mutant bestrophin 1 modulators for the treatment of BEST 1-related retinopathy |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001036004A2 (en) * | 1999-11-15 | 2001-05-25 | Parker Hughes Institute | Use of egf genistein for treatment egf-receptor expressing cancers |
| CN1335133A (en) * | 2000-07-28 | 2002-02-13 | 蛋白质技术国际公司 | Composition and method for preventing and curing breast cancer |
-
2016
- 2016-10-17 CN CN201610902969.7A patent/CN106265631A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001036004A2 (en) * | 1999-11-15 | 2001-05-25 | Parker Hughes Institute | Use of egf genistein for treatment egf-receptor expressing cancers |
| CN1335133A (en) * | 2000-07-28 | 2002-02-13 | 蛋白质技术国际公司 | Composition and method for preventing and curing breast cancer |
Non-Patent Citations (2)
| Title |
|---|
| 《中国医科大学学报》 * |
| 《辽宁中医药大学学报》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110317872A (en) * | 2019-07-15 | 2019-10-11 | 汕头大学医学院第一附属医院 | It is used to prepare the molecular marked compound and kit of detection, prognosis and Diagnosis of Breast cancer product |
| CN115335045A (en) * | 2020-03-30 | 2022-11-11 | 雷根斯堡大学 | Mutant bestrophin 1 modulators for the treatment of BEST 1-related retinopathy |
| CN113842387A (en) * | 2021-11-19 | 2021-12-28 | 大连理工大学盘锦产业技术研究院 | Pharmaceutical composition of 10-hydroxycamptothecin and biochanin A and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Chu et al. | Berberine reverses epithelial-to-mesenchymal transition and inhibits metastasis and tumor-induced angiogenesis in human cervical cancer cells | |
| Yang et al. | The anti-cancer activity of Antrodia camphorata against human ovarian carcinoma (SKOV-3) cells via modulation of HER-2/neu signaling pathway | |
| CN107106580A (en) | The composition for the treatment of cancer stem cell | |
| CN106265631A (en) | Biochanin A purposes in preparation suppression breast carcinoma propagation, diversion medicaments and mammary cancer chemotherapy sensitizer | |
| CN104758292A (en) | A use of PD-0332991 in preparation of drugs preventing and treating drug-resistant tumor | |
| CN113230259A (en) | Pharmaceutical application of compound istradefylline capable of reversing drug resistance of paclitaxel | |
| CN103251585A (en) | Effects and application of artemisinin and its derivative in inhibition of platelet-derived growth factor receptor A | |
| CN102198125A (en) | Purpose of phenethyl caffeate derivatives in preparation of medicines for inhibiting angiogenesis of tumors | |
| CN107213145A (en) | Application of the Rabdocetsin B in the product for suppressing esophageal squamous cell cancer cell multiplication is prepared | |
| CN114010789B (en) | Application of bufadienolide compound in preparing medicament for treating EGFR and/or STAT3 driving diseases | |
| CN102961374B (en) | Application of compound and STAT3 (Signal Transducer and Activator of Transcription) inhibitor | |
| CN108714149A (en) | Purposes of the garden burnet active constituent in preparing anti-tumor drug | |
| US10675289B2 (en) | Methods of treating pancreatic cancer | |
| CN103301107A (en) | Application of luteolin in preparation of medicament for treating and preventing stomach cancer | |
| CN103565819A (en) | Composition for inhibiting tumor stem cells | |
| CN105169379A (en) | Tumor vaccine for treating stomach cancer and preparing method of tumor vaccine | |
| CN104906578A (en) | Application of proton pump inhibitor in preparation of medicine for treating hepatocellular carcinoma | |
| CN103800905A (en) | Method for treating cancer by combined application of c-MET inhibitor and sodium butyrate | |
| CN103933569B (en) | Anti-lung cancer pharmaceutical composition, its application, pill case and package | |
| CN102526033B (en) | Composition prepared from epigallocatechin gallate and mitomycin C and used for suppressing tumor cell proliferation | |
| CN102337332A (en) | Gene and application of protein encoded by gene to preparation of medicine for diagnosing and treating breast cancer | |
| CN106822100A (en) | A kind of composition and pharmaceutical preparation and its application | |
| CN104173354B (en) | Can treating cancer pharmaceutical compositions | |
| Wu | In vivo and in vitro Investigations on the Anti-metastatic Effects of Triterpenoid Actein in Breast Cancer and the Underlying Mechanisms | |
| CN104840463B (en) | A kind of pharmaceutical composition and detection method for promoting Increase Apoptosis of Lung Cancer Cells |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170104 |
|
| RJ01 | Rejection of invention patent application after publication |